An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris

Trial Profile

An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2014

At a glance

  • Drugs CB 03 01 (Primary)
  • Indications Acne vulgaris
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Intrepid Therapeutics
  • Most Recent Events

    • 29 May 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 12 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top